Cellular uptake and intracellular fate of antisense oligonucleotides

Alain R. Thierry, Eric Vives, Jean Philippe Richard, Paul Prevot, Camille Martinand-Mari, Ian Robbins, Bernard Lebleu

Research output: Contribution to journalReview article

Abstract

Antisense oligonucleotides and short interfering RNAs are routinely used for gene function analysis and are being developed for clinical applications. The mechanism underlying internalization of free oligonucleotides into cells is poorly understood and inefficient in most cases. Antisense oligonucleotide delivery into ex vivo cells is routinely improved by the addition of cationic lipids. New chemical modifications and vectors allowing improved cellular delivery in vivo are being developed.

Original languageEnglish (US)
Pages (from-to)133-138
Number of pages6
JournalCurrent Opinion in Molecular Therapeutics
Volume5
Issue number2
StatePublished - Apr 1 2003

    Fingerprint

Keywords

  • Antisense oligonucleotides
  • Cellular uptake
  • Delivery vectors

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

Thierry, A. R., Vives, E., Richard, J. P., Prevot, P., Martinand-Mari, C., Robbins, I., & Lebleu, B. (2003). Cellular uptake and intracellular fate of antisense oligonucleotides. Current Opinion in Molecular Therapeutics, 5(2), 133-138.